NCT05120284View on ClinicalTrials.gov

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

August 31, 2026

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Dichloroacetate (DCA)

"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."

GENETIC

Genotype

Participants will be genotyped to determine GSTZ1 haplotype status.

Trial Locations (2)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27587

Wake Forest University, Winston-Salem

All Listed Sponsors
lead

University of Florida

OTHER